Kisqali Improves Outcomes and Survival Rates in Women With Metastatic Breast Cancer

SAN ANTONIO—Women with advanced breast cancer may benefit from a therapy that combines ribociclib (Kisqali, Novartis) with endocrine therapy. The combination extended progression-free survival in women with hormone receptor–positive (HR+)/HER2– advanced breast cancer compared with endocrine therapy alone, according to a report presented at the 2018 San Antonio Breast Cancer Symposium.